Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary ...

Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

The drug received accelerated approval in 2016 for use either in combination with ursodeoxycholic acid (UDCA) for those with ...

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE ...

A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions, uncertainties and a need to redefine what life looks like with a chronic ...

(RTTNews) - Primary Biliary Cholangitis is a rare, progressive, chronic autoimmune disease of the liver in which the small bile ducts are gradually destroyed, causing bile and other toxins to build up ...

The Business Research Company's Primary Biliary Cholangitis Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ...